Ph.D., Iowa State University
Postdoc, California Institute of Technology
Dr. Wu served as Senior fellow/project manager at Schering-Plough with 20+ years of experience in experience in the pharmaceutical industry, with pioneering contributions in the development of new drugs for oncology, cardiovascular disease, diabetes, obesity, Alzheimer’s disease, etc. Over years, Dr. Wu has published 100+ peer reviewed research articles and obtained 50+ issued US/EU/Chinese patents
New Jersey Minority Contribution Award, 2005
Schering-Plough research & development president’s award, 2016
National Distinguished Expert, China, 2012
Ph.D., Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
Postdoc, University of Pittsburgh and Scripps Research Institute
Dr. Chen has successively served as the senior executive in well-known domestic and multinational pharmaceutical companies, such as Versicor Pharmaceuticals, Roche Pharmaceuticals, Furen Medicines, etc. He has over 25 years of experience in new drug research and development, with expertise in areas such as oncology, diabetes, antivirals, autoimmune diseases, and antibiotics with extensive international experience in new drug R&D and project management
Published nearly 30 peer-reviewed research articles
Obtained nearly 40 issued US/EU/Chinese patents
M.Med, Shanghai University of Traditional Chinese Medicine
5 years of clinical experience as an attending physician.
Before joining TYK Medicines, Mr. Chen served as medical manager at Betta Pharmaceutical, medical development director at Ascletis Pharma Inc and Yangtze River Pharmaceutical Group, and chief engineer assistant/clinical pharmacology center director at Minsheng Pharma.
With over 20 years of experience in clinical development and registration of new drugs, Mr. Chen has in-depth knowledge of clinical development strategy, clinical trial design, clinical trial execution, and clinical operations in the fields of oncology, liver diseases, hematology, digestive diseases, and skin diseases. He has directly led or participated in the clinical development and registration for marketing of 10+ innovative drugs, including Icotinib, Ensartinib, Danoprevir, and Acetylcysteine Injection, which have been marketed in China.
PhD in Pharmacy, China Pharmaceutical University
Master in Finance, Fordham University
FRM Charter Holder
2009-2011 KPMG, Auditor
2011-2013 KPMG, Consultant
2015-2018 Shanghai Pudong Science and Technology Investment Co., Ltd, Risk Manager
2018-2019 Zheshang Securities Co., Ltd, Senior Research Fellow
2019-present TYK Medicines Inc, Secretary of the Board of Directors
Independently lead Investment&Financing Department, accomplish billion level equity financing.
Independently lead series of new drug M&A projects and license-out projects worth of hundred million level.